This medication is taken by injection.
Glatiramer acetate injection is an FDA-approved therapeutic equivalent to Copaxone® (glatiramer acetate injection) available in two dose strengths: 40 mg/mL for 3-times-a-week injection and 20 mg/mL for one-daily injection.
Glatiramer acetate is a synthetic protein that simulates myelin basic protein, a component of the myelin that insulates nerve fibers in the brain and spinal cord. This drug seems to block myelin-damaging T-cells through a mechanism that is not completely understood.
Glatiramer acetate injection is approved by the U.S. Food and Drug Administration (FDA) for the treatment of relapsing forms of multiple sclerosis, which include clinically isolated syndrome, relapsing-remitting disease (RRMS) and active secondary progressive disease (SPMS with relapses).
Click here to read the FDA prescribing information for healthcare professionals for Mylan’s 40 mg glatiramer acetate
To read the Patient Information for glatiramer acetate 40 mg dosing, scroll down to page 17.
Click here to read the FDA prescribing information for healthcare professionals for Mylan’s 20mg glatiramer acetate.
To read the Patient Information for glatiramer acetate 20 mg dosing, scroll down to page 17.
SupportMYLAN SUPPORT PROGRAM
Financial Assistance ProgramMylan MS Advocate™ Co-pay Program